Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors

By Ming Yi, D. Jiao, Hanxiao Xu, Qian Liu, Weiheng Zhao, Xinwei Han, Kongming Wu. Molecular Cancer, 2018

636 citations recorded by the source corpus.

Programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) is a negative modulatory signaling pathway for activation of T cell. It is acknowledged that PD-1/PD-L1 axis plays a crucial role in the progression of tumor by altering status of immune surveillance. As one of the most promising immune therapy strategies, PD-1/PD-L1 inhibitor is a breakthrough for the therapy of some refractory tumors. However, response rate of PD-1/PD-L1 inhibitors in overall patients is unsatisfactory, which limits the application in clinical practice. Therefore, biomarkers which could effectively predict the efficacy of PD-1/PD-L1 inhibitors are crucial for patient selection. Biomarkers reflecting tumor immune microenvironment and tumor cell intrinsic features, such as PD-L1 expression, density of tumor infiltrating lymphocyte (TIL), tumor mutational burden, and mismatch-repair (MMR) deficiency, have been noticed to associate with treatment effect of anti-PD-1/anti-PD-L1 therapy. Furthermore, gut microbiota, circulating biomarkers, and patient previous history have been found as valuable predictors as well. Therefore establishing a comprehensive assessment framework involving multiple biomarkers would be meaningful to interrogate tumor immune landscape and select sensitive patients.

View Paper: https://www.semanticscholar.org/paper/2d174a8e7d22c78edbe41f0254061f64be8a417c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

  1. Shuang Qin
  2. Ming Yi
  3. Linping Xu
  4. Kongming Wu
  5. Shengnan Yu
  6. S. Luo

Citations in the corpus